A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Inclusion:
Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:
Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb)
Documented evidence of progressive disease(PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by the IMWG criteria
Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent
Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 to 2 at screening and immediately before the start of study treatment administration
Exclusion:
Participate-In-This-Study1@its.jnj.com844-434-4210
Irvine, California 92618, United States
Eugene, Oregon 97401, United States
Chaoyang District, 100020, China
Gunma, 377-0280, Japan
Brzozów, 36 200, Poland
Krakow, 30 688, Poland
Lodz, 93 513, Poland
Wroclaw, 50 367, Poland
Jeollanam-do, 58128, South Korea